Assembly Biosciences Raises $100M Through $26.50 Share Offering
Assembly Biosciences is selling 3,358,602 common shares at $26.50 each and 415,000 pre-funded warrants at $26.499, expected to generate approximately $100 million in gross proceeds. The company also granted a 30-day option for 566,040 additional shares, with funds earmarked for clinical development and general corporate use.
1. Offering Details
Assembly Biosciences has underwritten the sale of 3,358,602 common shares at $26.50 each alongside 415,000 pre-funded warrants at $26.499, aiming to raise roughly $100 million in gross proceeds. Underwriters also hold a 30-day option to purchase up to 566,040 additional shares at the same price less discounts and commissions.
2. Investor Participation
The financing attracted both new and existing investors, including Gilead Sciences, Commodore Capital, Farallon Capital Management, Seven Fleet Capital, Sirenia Capital Management, Columbia Threadneedle Investments, Paradigm BioCapital Advisors, Squadron Capital Management and other healthcare-focused funds.
3. Use of Proceeds and Timing
Net proceeds will support clinical development of pipeline therapeutics and general corporate purposes. The offering is expected to close on or about May 26, 2026, pending customary closing conditions.